Celcuity Inc. (NASDAQ:CELC) Short Interest Update

Celcuity Inc. (NASDAQ:CELC) was the target of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 3,330,000 shares, a growth of 6.4% from the January 15th total of 3,130,000 shares. Based on an average daily volume of 283,600 shares, the short-interest ratio is currently 11.7 days.

Institutional Trading of Celcuity

Hedge funds have recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new position in Celcuity in the third quarter valued at $33,000. Prospera Private Wealth LLC acquired a new stake in shares of Celcuity during the 3rd quarter valued at about $35,000. Summit Investment Advisors Inc. increased its stake in shares of Celcuity by 49.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company’s stock valued at $45,000 after purchasing an additional 1,132 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in Celcuity in the 4th quarter worth about $50,000. Finally, Values First Advisors Inc. acquired a new position in Celcuity in the 3rd quarter worth about $86,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Stock Performance

Shares of NASDAQ CELC traded up $0.26 during midday trading on Monday, reaching $12.88. 148,960 shares of the stock were exchanged, compared to its average volume of 225,983. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The firm has a market cap of $478.23 million, a price-to-earnings ratio of -4.93 and a beta of 0.73. The firm has a 50-day simple moving average of $12.26 and a two-hundred day simple moving average of $14.10. Celcuity has a twelve month low of $10.35 and a twelve month high of $22.19.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CELC. Needham & Company LLC increased their price target on shares of Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Celcuity in a report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Celcuity currently has a consensus rating of “Buy” and a consensus target price of $30.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.